Kinfo
Organon & Co. logo

Organon & Co.

OGNNYSEHealthcare·US · USD
$13.72
+0.01 (+0.07%)
Prices as of October 2, 2026 · market closed

Price

Key statistics

Valuation
Market cap3.60B USD
Enterprise value11.02B USD
Trailing P/E17.58
Forward P/E3.79
PEG ratio-0.66
Price / sales0.59
Price / book3.58
Profitability
Gross margin54.36%
Operating margin20.73%
Profit margin3.41%
Return on assets5.67%
Return on equity24.04%
Income (TTM)
Revenue6.13B USD
Gross profit3.27B USD
EBITDA1.68B USD
Net income209.00M USD
Diluted EPS$0.78
Rev. growth (YoY)-2.30%
Balance sheet
Total cash1.13B USD
Total debt8.55B USD
Debt / equity850.20
Current ratio1.95
Book value / share$3.83
Cash flow (TTM)
Operating cash flow737.00M USD
Levered free cash flow490.75M USD
Shares & price
Shares outstanding262.61M
Float242.99M
Held by institutions84.80%
Beta1.52
50-day MA$13.67
200-day MA$10.86
52-week high$13.79
52-week low$5.69
Dividends
Forward rate
$0.08
Yield
0.58%
Payout ratio
10.26%
Frequency
Quarterly
Recent payments
  • 2026-08-14$0.02
Earnings (EPS)
DateEst.ActualSurprise2026-07-311.070.85−20.56%2026-04-300.850.71−16.47%2026-02-120.730.63−13.70%2026-01-281.031.03+0.00%2025-12-030.270.45+66.67%
About Organon & Co.

Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine. The company serves patients and healthcare providers in more than 140 markets through wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its women’s health business is a central part of the portfolio, supported by biosimilars and well-known legacy brands that address everyday treatment needs across multiple therapeutic areas. Organon & Co. operates as a diversified healthcare provider with a strong international footprint and a product mix designed to meet ongoing demand for prescription treatments and essential medicines.

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Kevin Ali
Employees
10,000
Headquarters
Jersey City, NJ, United States

Frequently asked questions about Organon & Co.